New Hampshire Trust Has $1.22 Million Stock Position in Amgen Inc. (NASDAQ:AMGN)

New Hampshire Trust lifted its position in Amgen Inc. (NASDAQ:AMGN) by 3.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 4,662 shares of the medical research company’s stock after acquiring an additional 158 shares during the period. New Hampshire Trust’s holdings in Amgen were worth $1,215,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in the company. Capital Performance Advisors LLP purchased a new position in Amgen during the 3rd quarter worth approximately $25,000. Hershey Financial Advisers LLC purchased a new position in shares of Amgen during the second quarter valued at $30,000. Legacy Investment Solutions LLC purchased a new position in shares of Amgen during the third quarter valued at $29,000. Matrix Trust Co acquired a new position in Amgen during the third quarter valued at $36,000. Finally, Livelsberger Financial Advisory purchased a new stake in Amgen in the 3rd quarter worth about $56,000. Institutional investors and hedge funds own 76.50% of the company’s stock.

Amgen Stock Up 1.0 %

AMGN stock opened at $272.11 on Tuesday. The stock has a market capitalization of $146.27 billion, a price-to-earnings ratio of 34.84, a price-to-earnings-growth ratio of 2.68 and a beta of 0.56. The company has a 50-day moving average of $273.95 and a two-hundred day moving average of $307.18. Amgen Inc. has a 52-week low of $253.30 and a 52-week high of $346.85. The company has a debt-to-equity ratio of 7.55, a current ratio of 1.32 and a quick ratio of 0.96.

Amgen (NASDAQ:AMGN) last announced its earnings results on Wednesday, October 30th. The medical research company reported $5.58 earnings per share for the quarter, beating the consensus estimate of $5.11 by $0.47. The firm had revenue of $8.50 billion during the quarter, compared to the consensus estimate of $8.50 billion. Amgen had a return on equity of 168.35% and a net margin of 13.00%. The firm’s revenue for the quarter was up 23.2% compared to the same quarter last year. During the same quarter in the prior year, the company earned $4.96 EPS. As a group, equities research analysts anticipate that Amgen Inc. will post 19.57 EPS for the current year.

Amgen Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, February 14th will be paid a dividend of $2.38 per share. This is a boost from Amgen’s previous quarterly dividend of $2.25. This represents a $9.52 annualized dividend and a yield of 3.50%. The ex-dividend date is Friday, February 14th. Amgen’s dividend payout ratio is presently 121.90%.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the company. StockNews.com downgraded Amgen from a “strong-buy” rating to a “buy” rating in a report on Wednesday, December 18th. Jefferies Financial Group reiterated a “buy” rating and issued a $380.00 price objective on shares of Amgen in a research note on Tuesday, November 12th. Deutsche Bank Aktiengesellschaft decreased their target price on shares of Amgen from $305.00 to $285.00 in a research note on Wednesday, November 27th. Wells Fargo & Company dropped their price target on shares of Amgen from $335.00 to $280.00 and set an “equal weight” rating on the stock in a research note on Friday, January 10th. Finally, William Blair reissued an “outperform” rating on shares of Amgen in a research report on Tuesday, November 12th. Two equities research analysts have rated the stock with a sell rating, twelve have issued a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Amgen presently has a consensus rating of “Hold” and a consensus target price of $314.91.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.